Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs.
NTLA - Intellia Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$23.40
DETAILS
HIGH:
$49.00
LOW:
$9.00
MEDIAN:
$20.50
CONSENSUS:
$23.40
UPSIDE:
83.96%
Stock News
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second quarter ended June 30, 2026.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Brokerages
Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-three research firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and one
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates.
Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA
Amova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 10.0% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,973,061 shares of the company's stock after selling 219,400 shares during the quarter. Amova Asset Management
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
It might pull it off, provided several things fall right in place.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FDA approval of Yartemlea and a significant development deal with Novo Nordisk.
Dow Extends Record Run as Fed Decision Looms
Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once again
This Stock Is Up 58% This Year. Is It too Late to Buy?
There could be additional catalysts for this drugmaker over the next year.
Price Targets
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
$24.00
(was $11.24)
Evercore ISI
Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
$9.00
(was $13.04)
Andy Chen
·
Wolfe Research
Intellia Therapeutics price target raised to $17 from $12 at Wedbush
$17.00
(was $14.71)
Wedbush
H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)
$25.00
(was $12.11)
New Street
Intellia Therapeutics price target raised to $17 from $13 at Bernstein
$17.00
(was $13.99)
Bernstein
Intellia Therapeutics price target lowered to $49 from $58 at Canaccord
$49.00
(was $14.42)
Canaccord Genuity
Intellia Therapeutics price target raised to $30 from $27 at Chardan
$30.00
(was $13.03)
Chardan Capital
Intellia Therapeutics price target raised to $35 from $29 at Leerink
$35.00
(was $13.21)
Leerink Partners
Intellia Therapeutics price target raised to $15 from $11 at Morgan Stanley
$15.00
(was $14.07)
Morgan Stanley
Intellia Therapeutics price target raised to $13 from $7 at Baird
$13.00
(was $13.94)
Jack Allen
·
Robert W. Baird
Intellia Therapeutics (NTLA) PT Raised to $25 at H.C. Wainwright
$25.00
(was $13.95)
KeyBanc
Intellia Therapeutics (NTLA) PT Raised to $7 at Baird
$7.00
(was $14.39)
Jack Allen
·
Robert W. Baird
Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
$8.00
(was $9.73)
Evercore ISI
Intellia Therapeutics price target lowered to $14 from $25 at Truist
$14.00
(was $9.91)
Truist Financial
Intellia Therapeutics price target lowered to $27 from $33 at Oppenheimer
$27.00
(was $9.87)
Oppenheimer
Intellia Therapeutics price target lowered to $9 from $14 at Wedbush
$9.00
(was $12.49)
David Nierengarten
·
Wedbush
Intellia Therapeutics price target lowered to $18 from $25 at H.C. Wainwright
$18.00
(was $13.12)
Mitchell Kapoor
·
H.C. Wainwright
Intellia Therapeutics (NTLA) PT Lowered to $9 at Baird
$9.00
(was $13.12)
Jack Allen
·
Robert W. Baird
Intellia Therapeutics price target lowered to $29 from $33 at Citizens JMP
$29.00
(was $14.79)
JMP Securities
Intellia Therapeutics downgraded to Market Perform from Outperform at Bernstein
$14.50
(was $14.79)
Bernstein